Pathophysiology and clinical significance of atherosclerotic plaque rupture

Cardiovascular Research

Volumn 41, Issue 2, 1999, Pages 323-333

  Gutstein, David E ^a   Fuster, Valentin ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Atherosclerosis; Coronary disease; Infarction; Ischemia; Thrombosis

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTIANGINA PECTORIS AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HIRUDIN; HIRULOG; NITRIC ACID DERIVATIVE;

ATHEROSCLEROTIC PLAQUE; CLINICAL FEATURE; CORONARY ARTERY THROMBOSIS; DISEASE CLASSIFICATION; FIBRINOLYTIC THERAPY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HISTOPATHOLOGY; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; Q WAVE; REVIEW; SUDDEN DEATH; THROMBOGENICITY; UNSTABLE ANGINA PECTORIS; VASOSPASM;

ADRENERGIC BETA-ANTAGONISTS; ANTICHOLESTEREMIC AGENTS; CORONARY ARTERIOSCLEROSIS; CORONARY THROMBOSIS; CORONARY VESSELS; FIBRINOLYTIC AGENTS; HUMANS; MYOCARDIAL INFARCTION;

EID: 0033021172     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(98)00322-8     Document Type: Review

References (110)

1. Fuster V., Gotto A.M., Libby P., Loscalzo J., McGill H.C. 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Pathogenesis of coronary disease: the biologic role of risk factors. J Am Coll Cardiol. 27:1996;964-976.
2. Braunwald E., Jones R.H., Mark D.B.et al. Diagnosing and managing unstable angina. Circulation. 90:1994;613-622.
3. Pedersen T.R., Kjekshus J., Berg K.et al. Cholesterol lowering and the use of healthcare resources: results of the Scandinavian Simvastatin Survival Study. Circulation. 93:1996;1796-1802.
4. Herrick J.B. Clinical features of sudden obstruction of the coronary arteries. J Am Med Assoc. 59:1912;2015-2020.
5. White H.D., Van de Werf F.J.J. Thrombolysis for acute myocardial infarction. Circulation. 97:1998;1632-1646.
6. Ambrose J.A., Weinrauch M. Thrombosis in ischemic heart disease. Arch Intern Med. 156:1996;1382-1394.
7. Davies M.J. The composition of coronary artery plaques. New Engl J Med. 336:1997;1312-1314.
8. Falk E., Shah P.K., Fuster V. Coronary plaque disruption. Circulation. 92:1995;657-671.
9. Fuster V., Fallon J.T., Nemerson Y. Coronary thrombosis. Lancet. 348(Suppl):1996;s7-s10.
10. Burke A.P., Farb A., Malcolm G.T., Liang Y.H., Smialek J., Virmani R. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. New Engl J Med. 336:1997;1276-1281.
11. ISIS (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:349-360.
12. Gruppo Italiano per lo Studio della Streptochinasi Nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986;1:397-402.
13. Thom T.J., Epstein F.H. Heart disease, cancer, and stroke mortality trends and their interpretations: an international perspective. Circulation. 90:1994;574-582.
14. Goldberg R.J., Gorak E.J., Yarzebski J.et al. A community-wide perspective of sex differences and temporal trends in the incidence and survival rates after acute myocardial infarction and out-of-hospital deaths caused by coronary heart disease. Circulation. 87:1993;1947-1953.
15. Gillum R.F. Trends in acute myocardial infarction and coronary heart disease death in the United States. J Am Coll Cardiol. 23:1994;1273-1277.
16. Gheorghiade M., Ruzumna P., Borzak S., Havstad S., Ali A., Goldstein S. Decline in the rate of hospital mortality from acute myocardial infarction: impact of changing management strategies. Am Heart J. 131:1996;250-256.
17. Naylor C.D., Chen E. Population-wide mortality trends among patients hospitalized for acute myocardial infarction: the Ontario experience, 1981 to 1991. J Am Coll Cardiol. 24:1994;1431-1438.
18. Dellborg M., Eriksson P., Riha M., Swedberg K. Declining hospital mortality in acute myocardial infarction. Eur Heart J. 15:1994;5-9.
19. Gutstein D.E., Fuster V. Pathophysiologic bases for adjunctive therapies in the treatment and secondary prevention of acute myocardial infarction. Clin Cardiol. 21:1998;161-168.
20. Gotto A.M. Cholesterol management in theory and practice. Circulation. 96:1997;4424-4430.
21. The PARAGON Investigators. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. Circulation 1998;97:2386-2395.
22. Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators. Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation: a pilot study. Circulation 1997;96:769-777.
23. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. New Engl J Med 1998;338:1498-1505.
24. The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators. New Engl J Med 1997;336:1621-1628.
25. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. New Engl J Med 1998;338:1488-1497.
26. Stary H.C., Chandler A.B., Dinsmore R.E.et al. A definition of advanced types of atherosclerotic lesions and a histologic classification of atherosclerosis: a report from the Committee on Arteriosclerosis. American Heart Association. Circulation. 92:1995;1355-1374.
27. Lorce H.M., Tobias B.J., Gibson L.J. Mechanical properties of model atherosclerotic lesion lipid pools. Arteriosclr Thromb. 14:1994;230-234.
28. Moreno P.R., Falk E., Palacios I.F., Newell J.B., Fuster V., Fallon J.T. Macrophage infiltration in acute coronary syndromes: implications for plaque rupture. Circulation. 90:1994;775-778.
29. van der Wal A.C., Becker A.E., van der Loos C.M., Das P.K. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation. 89:1994;36-44.
30. Mann J.M., Davies M.J. Vulnerable plaque: relation of characteristics to degree of stenosis in human coronary arteries. Circulation. 94:1996;928-931.
31. Richardson P.D., Davies M.J., Born G.V. Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet. 2:1989;1462-1463.
32. Ambrose J.A., Tannenbaum M., Alexpoulos D.et al. Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol. 12:1988;56-62.
33. Mintz G.S., Pichard A.D., Popma J.J.et al. Determinants and correlates of target lesion calcium in coronary artery disease: a clinical, angiographic and intravascular ultrasound study. J Am Coll Cardiol. 29:1997;268-274.
34. Fuster V., Lewis A. Conner Memorial Lecture. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation. 90:1994;2126-2146.
35. Davies M.J. Stability and instability: two faces of coronary atherosclerosis. Circulation. 94:1995;2013-2019.
36. Fuster V., Badimon L., Badimon J.J., Chesebro J.H. The pathogenesis of coronary artery disease and the acute coronary syndromes. New Engl J Med. 326:1992;310-318.
37. Shah P.K., Falk E., Badimon J.J.et al. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques: potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation. 92:1995;1565-1569.
38. Galis Z.S., Sukhova G.K., Kranzhofer R., Clark S., Libby P. Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases. Proc Natl Acad Sci USA. 92:1995;402-406.
39. Libby P. Molecular basis of the acute coronary syndromes. Circulation. 91:1995;2844-2850.
40. Rajagopalan S., Meng X.P., Ramasamy S., Harrison D.G., Galis Z.S. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vivo: implications for atherosclerotic plaque stability. J Clin Invest. 98:1996;2572-2579.
41. Schecter A.D., Rollins B.J., Zhang Y.J.et al. Tissue factor is induced by monocyte chemoattractant protein-1 in human aortic smooth muscle and THP-1 cells. J Biol Chem. 272:1997;28568-28573.
42. Bjorkerud S., Bjorkerud B. Apoptosis is abundant in human atherosclerotic lesions, especially in inflammatory cells (macrophages and T cells), and may contribute to the accumulation of gruel and plaque instability. Am J Pathol. 149:1996;367-380.
43. Melnick J.L., Adam E., DeBakey M.E. Possible role of cytomegalovirus in atherogenesis. J Am Med Assoc. 263:1990;2204-2207.
44. Pasceri V., Cammarota G., Patti G.et al. Association of virulent Helicobacter pylori strains with ischemic heart disease. Circulation. 97:1998;1675-1679.
45. Campbell L.A., O'Brien E.R., Cappuccio A.L.et al. Detection of Chlamydia pneumoniae TWAR in human coronary atherectomy tissues. J Infect Dis. 172:1995;585-588.
46. Gupta S., Leatham E.W., Carrington D., Mendall M.A., Kaski J.C., Camm A.J. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation. 96:1997;404-407.
47. Gurfinkel E., Bozovich G., Daroca A., Beck E., Mautner B. for the ROXIS Study Group. Randomized trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS pilot study. Lancet. 350:1997;404-407.
48. Wang P., Ba Z.F., Chaudry I.H. Administration of tumor necrosis factor-α in vivo depresses endothelium-dependent relaxation. Am J Physiol. 266:1994;H2535-H2541.
49. Bhagat K., Moss R., Collier J.et al. Endothelial "stunning" following a brief exposure to endotoxin: a mechanism to link infection and infarction? Cardiovasc Res. 32:1996;822-829.
50. Smith P.D., Saini S.S., Raffeld M., Manischewitz J.F., Wahl S.M. Cytomegalovirus induction of tumor necrosis factor-α by human monocytes and mucosal macrophages. J Clin Invest. 90:1992;1642-1648.
51. Witzum J.L., Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest. 88:1991;1785-1792.
52. Lapenna D., de Gioia S., Ciofani G.et al. Glutathione-related antioxidant defenses in human atherosclerotic plaques. Circulation. 97:1998;1930-1934.
53. Han D.K.M., Haudenschild C.C., Hong M.K., Tinkle B.T., Leon M.B., Liau G. Evidence for apoptosis in human atherogenesis and in a rat vascular injury model. Am J Pathol. 147:1995;267-277.
54. Kockx M.M., De Meyer G.R.Y., Muhring J., Jacob W., Bult H., Herman A.G. Apoptosis and related proteins in different stages of human atherosclerotic plaques. Circulation. 97:1998;2307-2315.
55. Geng Y.J., Wu Q., Muszynski M., Hansson G.K., Libby P. Apoptosis of vascular smooth muscle cells induced by in vitro stimulation with interferon-γ, tumor necrosis factor-α, and interleukin-1β Arterioscler Thromb Vasc Biol. 16:1996;19-27.
56. Kockx M.M., De Meyer G.R., Buyssens N., Knaapen M.W., Bult H., Herman A.G. Cell composition, replication, and apoptosis in atherosclerotic plaques after 6 months of cholesterol withdrawal. Circ Res. 83:1998;378-387.
57. Moreno P.R., Bernardi V.H., Lopez-Cuellar J.et al. Macrophages, smooth muscle cells and tissue factor in unstable angina: implications for cell mediated thrombogenicity in acute coronary syndromes. Circulation. 94:1996;3090-3097.
58. Toschi V., Gallo R., Lettino M.et al. Tissue factor predicts the thrombogenicity of human atherosclerotic plaque components. Circulation. 95:1997;594-599.
59. Mizuno K., Satomura K., Miyamoto A.et al. Angioscopic evaluation of coronary artery thrombi in acute coronary syndromes. New Engl J Med. 326:1992;287-291.
60. Uchida Y., Masuo M., Tomaru T., Kato A., Sugimoto T. Fiberoptic observation of thrombosis and thrombolysis in isolated human coronary arteries. Am Heart J. 112:1986;691-696.
61. Stringer H.A., van Swieten P., Heijnen H.F., Sixma J.J., Pannekoek H. Plasminogen activator inhibitor-1 released from activated platelets plays a key role in thrombolysis resistance: studies with thrombi generated in the Chandler loop. Arterioscler Thromb. 14:1994;1452-1458.
62. Fernandez-Ortiz A., Badimon J.J., Falk E.et al. Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture. J Am Coll Cardiol. 23:1994;1562-1569.
63. Banner D.W., D'Arcy A., Chene C.et al. The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor. Nature. 380:1996;41-46.
64. Miller G.J., Bauer K.A., Cooper J.A., Rosenberg R.D. Activation of the coagulant pathway in cigarette smokers. Thromb Haemost. 79:1998;549-553.
65. Stubbs P., Seed M., Moseley D., O'Connor B., Collinson P., Noble M. A prospective study of the role of lipoprotein(a) in the pathogenesis of unstable angina. Eur Heart J. 18:1997;603-607.
66. Woodward M., Lowe G.D., Rumley A., Tunstall-Pedoe H. Fibrinogen as a risk factor for coronary heart disease and mortality in middle-aged men and women: The Scottish Heart Health Study. Eur Heart J. 19:1998;55-62.
67. Bogaty P., Hackett D., Davies G., Maseri A. Vasoreactivity of the culprit lesion in unstable angina. Circulation. 90:1994;5-11.
68. Willerson J.T., Golino P., Eidt J., Campbell W.B., Buja M. Specific platelet mediators and unstable coronary artery lesions: experimental evidence and potential clinical implications. Circulation. 80:1989;198-205.
69. Theroux P., Fuster V. Acute coronary syndromes: unstable angina and non-Q-wave myocardial infarction. Circulation. 97:1998;1195-1206.
70. Aguirre F.V., Younis L.L., Chaitman B.R.et al. Early and 1-year clinical outcome of patients evolving non-Q-wave versus Q-wave myocardial infarction after thrombolysis: results from the TIMI II study. Circulation. 91:1995;2541-2548.
71. Zareba W., Moss A.J., Raubertas R.F. Risk of subsequent cardiac events in stable convalescing patients after first non-Q-wave and Q-wave myocardial infarction. Coron Artery Dis. 5:1994;1009-1018.
72. Braunwald E. Unstable angina: a classification. Circulation. 80:1989;410-414.
73. Hamm C.W., Goldman G.U., Heeschen C., Kreymann G., Berger J., Meinertz T. Emergency room triage of patients with acute chest pain by means of rapid testing for troponin T or troponin I. New Engl J Med. 337:1997;1648-1653.
74. Luscher M.S., Thygesen K., Ravkilde J., Heickendorff L. for the TRIM Study Group. Applicability of cardiac troponin T and I for early risk stratification in unstable coronary artery disease. Circulation. 96:1997;2578-2585.
75. Davies M.J., Thomas A. Thrombosis and acute coronary artery lesions in sudden cardiac ischemic death. New Engl J Med. 310:1984;1137-1140.
76. Demirovic J., Myerburg R.J. Epidemiology of sudden coronary death: an overview. Prog Cardiovasc Dis. 37:1994;39-48.
77. Janse M.J., Wit A.L. Electrophysiological mechanisms of ventricular arrhythmias resulting from myocardial ischemia and infarction. Physiol Rev. 69:1989;1049-1169.
78. Opitz C.F., Mitchell G.F., Pfeffer M.A., Pfeffer J.M. Arrhythmias and death after coronary occlusion in the rat: continuous telemetric ECG monitoring in conscious, untethered rats. Circulation. 92:1995;253-261.
79. Davies M.J. Anatomic features in victims of sudden coronary death: coronary artery pathology. Circulation. 85(Suppl I):1992;I19-I24.
80. Vanantiz J.M., Becker A.E. Sudden cardiac death and acute pathology of coronary arteries. Eur Heart J. 7:1986;987-991.
81. Warnes C.A., Roberts W.C. Sudden cardiac death: comparison of patients with to those without coronary thrombosis at necropsy. Am J Cardiol. 54:1984;1206-1211.
82. Burke A.P., Farb A., Malcom G.T., Liang Y., Smialek J., Virmani R. Effect of risk factors on the mechanism of acute thrombosis and sudden coronary death in women. Circulation. 97:1998;2110-2116.
83. Gheorghiade M., Bonow R.O. Chronic heart failure in the United States: a manifestation of coronary artery disease. Circulation. 97:1998;282-289.
84. TIMI IIIB Investigators. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction: results of the TIMI IIIB trial. Circulation 1994;89:1545-1556.
85. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994;308:81-106.
86. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. New Engl J Med 1994;330:956-961.
87. The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE Study. Lancet 1997;349:1429-1435.
88. Nicolini F.A., Lee P., Rios G., Kottke-Marchant K., Topol E.J. Combination of platelet fibrinogen receptor antagonist and direct antithrombin inhibitor at low doses markedly improves thrombolysis. Circulation. 89:1994;1802-1809.
89. Ohman E.M., Kleiman N.S., Gacioch G.et al. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with integrilin in acute myocardial infarction. Circulation. 95:1997;846-854.
90. Shebuski R.J., Stabilito I.J., Sitko G.R., Polokoff M.H. Acceleration of recombinant tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by the combination of heparin and the Arg-Gly-Asp-containing peptide bitistatin in a canine model of coronary thrombosis. Circulation. 82:1990;169-177.
91. Coller B.S. Inhibitors of the platelet glycoprotein IIb/IIIa receptor as conjunctive therapy for coronary artery thrombolysis. Coron Artery Dis. 3:1992;1016-1029.
92. Gold H.K., Coller B.S., Yasuda T.et al. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GP IIb/IIIa antibody in a canine preparation. Circulation. 77:1988;670-677.
93. White H.D., Aylward P.E., Frey M.J.et al. Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Circulation. 96:1997;2155-2161.
94. Cohen M., Demers C., Gurfinkel E.P.et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. New Engl J Med. 337:1997;447-452.
95. Fragmin during Instability in Coronary Artery Disease (FRISC) Study Group. Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996;347:561-568.
96. Shepherd J., Cobbe S.M., Ford I.et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. New Engl J Med. 333:1995;1301-1307.
97. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
98. The Cholesterol and Recurrent Events (CARE) Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New Engl J Med 1996;335:1001-1009.
99. Fuster V., Badimon J.J. Regression or stabilization of atherosclerosis means regression or stabilization of what we don't see in the arteriogram. Eur Heart J. 16:1995;6-12.
100. Waters D. Review of cholesterol-lowering therapy: coronary angiographic and events trials. Am J Med. 101(suppl 4A):1996;34S-39S.
101. Fuster V., Fallon J.T., Badimon J.J., Nemerson Y. The unstable atherosclerotic plaque: clinical significance and therapeutic intervention. Thromb Haemost. 78:1997;247-255.
102. Small D.M., Bond M.G., Waugh D., Prack M., Sawyer J.K. Physicochemical and histological changes in the arterial wall of nonhuman primates during progression and regression of atherosclerosis. J Clin Invest. 73:1984;1590-1605.
103. Kaplan J.R., Manuck S.B., Adams M.R., Williams J.K., Register T.C., Clarkson T.B. Plaque changes and arterial enlargement in atherosclerotic monkeys after manipulation of diet and social environment. Arterioscler Thromb. 13:1993;254-263.
104. Aikawa M., Rabkin E., Okada Y.et al. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization. Circulation. 97:1998;2433-2444.
105. Colli S., Eligini S., Lalli M., Camera M., Paoletti R., Tremoli E. Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis. Arterioscler Thromb Vasc Biol. 17:1997;265-272.
106. Treasure C.B., Klein J.L., Weintraub W.S.et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. New Engl J Med. 332:1995;481-487.
107. Anderson T.J., Meredith I.T., Yeung A.C., Frei B., Selwyn A.P., Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. New Engl J Med. 332:1995;488-493.
108. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 348:1996;1329-1339.
109. Johnstone M.T., Creager S.J., Scales K.M., Cusco J.A., Lee B.K., Creager M.A. Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation. 88:1993;2510-2516.
110. Woo K.S., Chook P., Lolin Y.I.et al. Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans. Circulation. 96:1997;2542-2544.